ProteinQure raises $11M in Series A funding, led by Tom Williams of Heron Rock Fund, to support its first clinical trial for PQ203 and advance pipeline programs.

May 28, 2025•7 months ago

Amount Raised

$11 Million

Round Type

series a

TorontoTherapeuticsBiotechnologyHealth Care

Investors

Kensington CapitalGolden VenturesHeron Rock FundTom Williams

Description

ProteinQure, a Toronto-based biotechnology company, has closed $11M in Series A financing. The funding will support the initiation of its first clinical trial for PQ203 and advance additional pipeline programs in neurology and nephrology. The round was led by Tom Williams of Heron Rock Fund, with participation from Golden Ventures and Kensington Capital. This funding brings the total amount raised to $16M.

Company Information

Company

ProteinQure

Location

Toronto, Ontario, Canada

About

ProteinQure is a biotechnology company developing computational peptide therapeutics. They focus on designing therapeutic peptides using a proprietary platform that combines machine learning, structural biology, and atomic-level simulations. Their innovations aim to enable tissue-specific delivery and access to novel target classes in various medical fields such as oncology and neurology. The company is advancing programs for challenges like triple-negative breast cancer.

Related People

5 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends